Immuno-Oncology and Technology is a peer-reviewed english-language open-access journal published by Elsevier in United Kingdom, operating under an open-access model since 2019. The journal covers Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens.
Authors are required to pay an article processing charge to publish in Immuno-Oncology and Technology; refer to the journal's APC page for the current rate. A waiver policy is offered for eligible authors. Articles are released under the CC BY-NC-ND license (see other journals using this license).
To date, Immuno-Oncology and Technology has published 1,230 articles. Articles are minted with DOIs through the prefix 10.1016.
Keywords
oncology, immunotherapy
At a glance
- Publisher
- Elsevier
- Country
- United Kingdom
- Primary language
- English
- License
- CC BY-NC-ND
- Peer review
- Anonymous peer review
- OA since
- 2019
- Review time
- 29 weeks
- DOI prefix
10.1016
ISSN
- electronic
- 2590-0188
Frequently asked questions
Is Immuno-Oncology and Technology peer-reviewed?
Yes — Immuno-Oncology and Technology operates a Anonymous peer review review process.
Does Immuno-Oncology and Technology charge an article processing charge (APC)?
Yes — refer to the journal's APC page for the current rate. A waiver policy is available for eligible authors.
What subjects does Immuno-Oncology and Technology publish?
Immuno-Oncology and Technology publishes research in Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens.
What languages does Immuno-Oncology and Technology accept?
Immuno-Oncology and Technology accepts manuscripts in English.
What is the ISSN of Immuno-Oncology and Technology?
ISSN:
2590-0188 (electronic).How do I submit a manuscript to Immuno-Oncology and Technology?
Submit through the journal's official portal: visit submission page →
How long does peer review take at Immuno-Oncology and Technology?
Average time from submission to publication is approximately 29 weeks.